

July 7, 2021



# Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021

*Presentation to highlight Company's current clinical study of lead compound LB-100 for Small Cell Lung Cancer*

ALTADENA, CA, July 07, 2021 (GLOBE NEWSWIRE) -- [Lixte Biotechnology Holdings, Inc.](#) (Nasdaq: LIXT) ("Lixte" or the "Company"), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will present at the MoneyShow July Virtual Expo taking place July 13-15, 2021. Registration is free and open to the public.

Event and Registration: [MoneyShow July Virtual Expo](#)  
Presentation Date: Wednesday, July 14, 2021  
Presentation Time: 3:20 p.m. ET

Lixte Founder and CEO John S. Kovach, M.D. will deliver a company overview, featuring the Company's ongoing Phase 1b/2 clinical trial with City of Hope, a world-renowned independent cancer research and treatment center, to assess LB-100 for treatment of extensive stage-disease small cell lung cancer.

## **About Lixte Biotechnology Holdings, Inc.**

[Lixte Biotechnology Holdings, Inc.](#) (Nasdaq:LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the "on" switches because the "off" switches, especially the master "off" switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, damaged by chemo or other cancer therapies, to continue to replicate before repairing the

damage, leading to the more efficient death and elimination of those cells from the body. Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds. The LB-100 compound, of which there are no competitors known to Lixte, is being tested in three clinical cancer treatment studies with others in planning. Additional information can be obtained at the company's website: [www.lihte.com](http://www.lihte.com)

### **Forward-Looking Statements**

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," "anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at [sec.gov/edgar.shtml](http://sec.gov/edgar.shtml).

### **Lixte Contact:**

[info@lihte.com](mailto:info@lihte.com)

General Phone: (631) 830-7092

Investor Phone: (888) 289-5533



Source: Lixte Biotechnology Holdings, Inc.